Vioxx / Rofecoxib News from Around the Web

NicOx Initiates Clinical Study to EvaluateHCT 3012 Effects on Blood Pressure Vs. Rofecoxib
source: Investor's Business Daily - 09-08-2004
SOPHIA ANTIPOLIS France Sep 8 2004 BUSINESS WIRE NicOx Nouveau Marche NicOx announces today that it has started a comparative clinical study to evaluate the effects of HCT 3012...

Study: Higher Doses of Vioxx can Raise Risk of Heart Attacks
source: Legal News Watch - 09-02-2004
Patients taking the highest recommended daily dosage of the arthritis drug Vioxx had three times the risk of heart attack or sudden cardiac death when compared to individuals...

Merck's Zocor Study Didn't Focus On Primary Mkt
source: Forbes Sciences - 08-31-2004
S P said However the study focused on high-risk cardiac patients not Zocor's primary market. The research firm said Merck also questions the negative findings of a recent Vioxx...

Wall Street pharma - Merck lower on Vioxx report; Gilead's shares gain - UPDATE
source: Profinance World Stock Market News - 08-27-2004
MS Sans Serif 4 LOS ANGELES Biotechnology and pharmaceutical stocks fell Thursday with Merck helping drag down the sector on word its Vioxx drug could increase the risk of cardiovascular...

Vioxx Patients Have 50% Greater Chance of Heart Attack Than Celebrex Patients
source: Investor's Business Daily - 08-26-2004
... have a 50 more likely chance of heart attack and sudden cardiac death than those using Pfizer's Celebrex. The data was presented in Bordeaux France at a conference of epidemiologists....

More Bad News for Merck
source: Business Week Daily Briefing - 08-26-2004
While Merck disputed the validity of the findings the FDA study could give more ammunition to Pfizer's sales reps as they battle for share in the intensely competitive market....

More Evidence: Vioxx Increases Heart Risks
source: WebMD - 08-26-2004
More Evidence Vioxx Increases Heart Risks High Doses Linked With Heart Attacks Sudden Cardiac Death By WebMD Medical News Reviewed By on Thursday August 26 2004 .lclist text-indent...

more. . .